| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | RECRUITING | PHASE3 | 2025-08-21 | 2033-08-30 | 2030-08-30 |
| NCT06564324 | A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients | RECRUITING | PHASE3 | 2024-11-27 | 2030-09 | 2029-01 |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2024-03-14 | 2027-10 | 2027-03 |
| NCT05303519 | Safusidenib Phase 2 Study in IDH1 Mutant Glioma | RECRUITING | PHASE2 | 2023-06-05 | 2028-03-01 | 2027-12-01 |
| NCT05609929 | Study the Effect of Omeprazole on AB-106 Pharmacokinetics | COMPLETED | PHASE1 | 2022-11-02 | 2023-01-20 | 2023-01-20 |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | WITHDRAWN | PHASE1, PHASE2 | 2022-09 | 2026-09 | 2025-06 |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | WITHDRAWN | PHASE1, PHASE2 | 2022-09 | 2026-07 | 2025-01 |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | TERMINATED | PHASE1, PHASE2 | 2022-03-29 | 2024-07-15 | 2024-07-15 |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | RECRUITING | PHASE2 | 2021-09-01 | 2027-06 | 2025-06 |
| NCT05357820 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK | COMPLETED | PHASE1 | 2021-07-19 | 2021-12-03 | 2021-12-03 |
| NCT05357911 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | COMPLETED | PHASE1 | 2021-07-13 | 2021-12-03 | 2021-08-20 |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | TERMINATED | PHASE1 | 2020-12-08 | 2022-08-31 | 2022-08-31 |
| NCT02279433 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | COMPLETED | PHASE1 | 2014-09 | 2019-03 | 2019-03 |